The efficacy and safety of combination therapy with alpha-blocker and low-dose propiverine hydrochloride for benign prostatic hyperplasia accompanied by overactive bladder symptoms

Korean Journal of Urology

Volumn 50, Issue 11, 2009, Pages 1078-1082

  Kang, Il Seo ^a   Sung, Zoo Hong ^a   Jong, Bouk Lee ^a  

^a National Medical Center   (South Korea)

Author keywords

Overactive urinary bladder; Prostatic hyperplasia

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROPIVERINE; TAMSULOSIN;

AGED; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; ORGAN SIZE; OVERACTIVE BLADDER; POSTVOID RESIDUAL URINE VOLUME; PROSPECTIVE STUDY; PROSTATE; PROSTATE HYPERTROPHY; QUALITY OF LIFE; URETHRA; UROFLOWMETRY;

EID: 72849112836     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2009.50.11.1078     Document Type: Article

References (25)

1. Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A. The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol 1988;35:515-520
2. Lepor H, Rigaud G. The efficacy of transurethral resection of the prostate in men with moderate symptoms of prostatism. J Urol 1990;143:533-537 (Pubitemid 20108145)
3. Knutson T, Edlund C, Fall M, Dahlstrand C. BPH with coexisting overactive bladder dysfunction - an everyday urological dilemma. Neurourol Urodyn 2001;20:237-247 (Pubitemid 32377204)
4. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008;54:419-426
5. Wadie BS, Ebrahim el-HE, Gomha MA. The relationship of detrusor instability and symptoms with objective parameters used for diagnosing bladder outlet obstruction: a prospective study. J Urol 2002;168:132-134
6. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care 2000;6(11 Suppl):S580-90. (Pubitemid 30649379)
7. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175:999-1004. (Pubitemid 43200054)
8. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-2256
9. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334-1338
10. Saito H, Yamada T, Oshima H, Morita T, Takeuchi S, Ando M, et al. A comparative study of the efficacy and safety of tamsulosin hydrochloride and combination of propiverine hydrochloride and tamsulosin hydrochloride in benign prostatic hyperplasia with pollakisuria and/or urinary incontinence. Jpn J Urol Surg 1999;12:525-536
11. Han DS, Kim H, Sul CK. The effects of combined therapy with propiverine (BUP-4®) after α-blocker on the improvements of quality of life scores in patients with benign prostatic hyperplasia accompanied with overactive bladder. Korean J Urol 2003;44:409-413
12. Kim HW, Seo SI, Ko JS, Jung JH, Lee JY. Incidence of overactive bladder in benign prostatic hyperplasia and the efficacy of combination therapy of alpha blocker with tolterodine. Korean J Urol 2003;44:1006-1010
13. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-2328 (Pubitemid 44749359)
14. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997;158:481-487 (Pubitemid 27327692)
15. Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006;175:1422-1426
16. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000;163:13-20.
17. Mochtar CA, Kiemeney LA, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FM, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 2003; 44:695-700. (Pubitemid 37542928)
18. Caulfield MP, Birdsall NJ. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 1998;50:279-290
19. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001; 19:299-306.
20. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006. (Pubitemid 47537675)
21. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-554 (Pubitemid 39345720)
22. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170: 530-547
23. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001;166:550-552 (Pubitemid 32652245)
24. Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004;93:745-750 (Pubitemid 38497022)
25. Jung YS, Hwang TK, Kim JC. The outcome and satisfaction of patients with lower urinary tract symptoms/benign prostatic hyperplasia following transurethral resection of the prostate according to urodynamic obstruction and the bladder function. Korean J Urol 2007;48:965-970 (Pubitemid 47496989)